New York City—January 25, 2010
“The standard treatment for lupus kidney disease is to block inflammation,” said Lionel Ivashkiv, M.D., associate chief scientific officer at Hospital for Special Surgery in New York City. “This study suggests you might want to target the macrophages, a specific type of white blood cell involved in the disease.”
For years, clinicians have known that kidney damage occurs in many patients with lupus, and they have known how the disease triggers the start of kidney disease. Little has been known, however, about one type of lupus kidney disease, proliferative crescentic disease that is associated with adverse outcomes and decreased survival. This type of kidney disease is characterized by abnormal proliferation (growth) of kidney cells that leads to irreversible damage to internal kidney structures that help filter waste and fluids from the blood. This advanced kidney disease leads to kidney failure and it is an important cause of the need for dialysis and transplantation in lupus.
Previous studies have suggested that type I interferons are implicated in promoting the autoimmunity associated with lupus. “We were interested in understanding whether these interferons might work directly on the kidney,” Dr. Ivashkiv said. “There is a lot of evidence that the interferons work on the immune system and we wanted to know how interferons affect kidney disease.”
To investigate, researchers used a mouse model of lupus. By increasing interferon production, they caused advanced kidney disease to occur in the mice rapidly. “The mice are a strain that will get nephritis over time, but we injected the mice at the very onset of the disease thus causing a very accelerated pattern, so that the mice have complete renal failure in two to four weeks,” Dr. Ivashkiv said. They then examined the changes that occurred during the development of the advanced kidney disease by drawing blood samples from the mice, and analyzing their kidneys, and analyzing the macrophages to determine their type, among other experiments.
In the type of kidney disease they were investigating, it has long been known that epithelial cells proliferating out of control form a kind of crescent. These crescent cells compress the glomerulus, the basic filtration unit of the kidney, and prevent it from functioning.
In their experiments, the investigators found that the development of these crescents was associated with infiltrating kidney macrophages that produced growth factors, and the infiltration of these was spurred by interferon type I. They also found that the type of macrophages involved were not the most common type of inflammatory macrophages but so called “alternatively activated macrophages” that are involved in wound healing and induce the proliferation of cells. This is what causes the proliferation and crescentic lesions in the kidney disease.
“This study suggests a new drug target. If you could understand how to target the macrophages and inhibit them or the growth factors that they produce, this might be a different approach to therapy,” Dr. Ivashkiv said. “This is an emerging area. Prior to this study, a role of macrophages had just been identified in lupus kidney disease, and this is the first study showing alternatively activated macrophages are involved in proliferative crescentic disease.”
The study was conducted by Dr. Lionel Ivashkiv and Dr. Antigoni Triantafyllopoulou, a rheumatology fellow at Hospital for Special Surgery. Dr. Anne Davidson, an expert in lupus models from the Feinstein Institute for Medical Research, Manhasset, N.Y., was a key collaborator. Other authors of the study are Claus-Werner Franzke, Giorgio Perino, and George D. Kalliolias from Hospital for Special Surgery; Surya V. Seshan from Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York; Meera Ramanujam from the Feinstein Institute for Medical Research and Nico van Rooijen from Vrije Universiteit Medical Center in Amsterdam, The Netherlands.
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s largest academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.